Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

30 closest matches · ranked by relevance

Phase 3 N=298 Addressing Involuntary Movements in Tardive Dyskinesia

Tardive Dyskinesia
Primary: Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) — -1.4; -2.1; -3.2; -3.3…
Auspex Pharmaceuticals, Inc. Results Apr 2018 5.5% serious AE View details

Phase 3 N=117 Aim to Reduce Movements in Tardive Dyskinesia

Tardive Dyskinesia
Primary: Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis — -3.0; -1.6 units…
Auspex Pharmaceuticals, Inc. Results Mar 2018 6.8% serious AE View details

Phase 3 N=119 Alternatives for Reducing Chorea in Huntington Disease

Chorea Associated With Huntington Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Entire…
Auspex Pharmaceuticals, Inc. Results Apr 2019 26.9% serious AE View details

Phase 2 N=253 Dyskinesia in Parkinson's Disease (Study P04501)

Parkinson Disease · Movement Disorders · Central Nervous System Diseases
Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753
Merck Sharp & Dohme LLC Results Feb 2017 4.9% serious AE View details